Tirzepatide Excites in Obesity Now Too, Says Lilly
The once-weekly investigational twincretin drug is in phase 3 development for obesity and under regulatory review, with a decision expected soon for type 2 diabetes.
Source: medscape.com
Stay updated with breaking news from James Marroquin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The once-weekly investigational twincretin drug is in phase 3 development for obesity and under regulatory review, with a decision expected soon for type 2 diabetes.